by 
The anti-neprilysin market includes a class of therapeutic drugs that inhibit neprilysin, a zinc metalloprotease enzyme involved in the degradation of various peptides in the body. Some of the key functions of neprilysin include regulation of blood pressure and fluid balance, and degradation of amyloid beta peptide, the aggregation of which is associated with Alzheimer’s disease. Currently, neprilysin inhibitors are being explored for the treatment of various conditions including heart failure, hypertension and Alzheimer’s disease.
The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
Neprilysin inhibitors are gaining popularity for the treatment of heart failure with reduced ejection fraction. The dual inhibition of neprilysin and angiotensin receptor helps in alleviating symptoms and reduces hospitalizations in heart failure patients. Ongoing clinical research is exploring new therapeutic applications of neprilysin inhibition in other disease indications as well.
Key Takeaways
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. Novartis’ Entresto, containing sacubitril and valsartan, currently dominates the neprilysin inhibitor market approved for heart failure treatment.
The increasing prevalence of heart failure worldwide is a major factor driving the growth of anti-neprilysin market. As per the American Heart Association, over 6 million Americans suffer from heart failure currently and half of the patients diagnosed with heart failure die within 5 years of diagnosis indicating a large unmet need.
Leading pharmaceutical companies are actively pursuing international expansion opportunities in major markets like China, India and several European countries to gain higher market share. Regional clinical trials and marketing authorization applications are helping companies launch neprilysin inhibitor products in various international geographies over the forecast period.
Market Key Trends
The combination of neprilysin inhibition with other drug classes like ARBs is a major trend being witnessed in the anti-neprilysin market currently. Specifically, the addition of neprilysin inhibition to ARB therapy has demonstrated significant improvements in heart failure outcomes. Ongoing research is exploring newer drug combinations involving neprilysin inhibitors to expand their role in heart failure treatment algorithms.
Porter’s Analysis
Threat of new entrants: Low barriers restrict entry with requirement of huge investments.
Bargaining power of buyers: Large pool of buyers with increasing demands bargain for better prices and quality.
Bargaining power of suppliers: Few suppliers and differentiation in products give them control over pricing and supply.
Threat of new substitutes: Alternate treatment options pose threat though high R&D and awareness keep anti-neprilysin market afloat.
Competitive rivalry: Fierce competition exists between major players to gain market share through innovative drugs and strategic collaborations.
Geographical Regions
North America leads the anti-neprilysin market in terms of value owing to high awareness, favorable reimbursement policies, and presence of major players.
Asia Pacific exhibits fastest growth driven by increasing geriatric population, growing healthcare expenditure, and rising incidence of heart failures in India and China.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
